Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

Invivyd (IVVD) and the SPEAR Study Group announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 in individuals with Long COVID or COVID vaccine injury. The Phase 2 clinical trial is expected to be initiated by mid-2026 and to include the following features: Multiple high doses of highly active monoclonal antibody VYD2311, an investigational antibody that has demonstrated in vitro antiviral activity across all clinically recorded variants of SARS-CoV-2 tested since the original Wuhan strain; Double-blind, placebo control; Inclusion criteria designed to enroll people with demonstrated persistent infection or antigenemia; Clinical efficacy evaluations including functional performance tests and Patient-Reported Outcomes assessment consistent across prior studies of Long COVID and other infection-associated chronic conditions and illnesses